Global Tetraspecific Antibodies Clinical Trials & Market Opportunity Report 2024 Featuring Innate Pharma, ModeX Therapeutics, Molecular Partners, OPKO Health, Sichuan Baili Pharmaceutical, SystImmune - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Global Tetraspecific Antibodies Clinical Trials & Market Opportunity Insight 2024" report has been added to ResearchAndMarkets.com's offering.Global Tetraspecific Antibod
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety
Innate Pharma SA Engages in Global Investor Conferences
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced members of its executive team are scheduled to participate in the upcoming conferences, detailed below.
Goldman Sachs Maintains INNATE PHARMA(IPHYF.US) With Hold Rating, Announces Target Price $2.71
Goldman Sachs analyst Rajan Sharma maintains $INNATE PHARMA(IPHYF.US)$ with a hold rating, and sets the target price at $2.71.According to TipRanks data, the analyst has a success rate of 30.6% and a
Innate Pharma Showcases Cancer Therapies at ASCO 2024
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
Top line results of TELLOMAK Phase 2 trial in mycosis fungoides confirming promising clinical activity of lacutamab Two posters on IPH6501, Innate's second generation ANKET, for the treatment of
Innate Pharma AGM Success and Company Outlook
Outcome of Innate Pharma's 2024 Annual General Meeting
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took place on May 23, 2024, in
Innate Pharma: Clarification Regarding SAR443579 Designation
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by Sanofi, it was mentioned that the molecule received breakthrough designation. This is an error. The molecule has US FDA Fast Track Designation, as communicated before in June 2023.
Innate Pharma Unveils Promising Cancer Therapies at EHA
Innate Pharma's Four Abstracts With Innate's Drug Candidates Accepted For The European Association Of Hematology 2024 Congress
Two abstracts on SAR443579 (IPH6101), ANKET platform lead asset, a trifunctional anti-CD123 NKp46xCD16 NK cell engager under development by partner Sanofi in blood cancerTwo abstracts on IPH6501, Inna
Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced today that four abstracts with Innate's drug candidates have been accepted for the European Association of Hematology (EHA) 2024 Congress, taking place June 13-16, 2024 in Madrid, Spain.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Curis (CRIS), Health Catalyst (HCAT) and Innate Pharma SA (OtherIPHYF)
Earnings Call Summary | Innate Pharma(IPHA.US) Q1 2024 Earnings Conference
The following is a summary of the Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript:Financial Performance:Innate Pharma has a firm cash status with about EUR115 million in cash as of the end
Innate Pharma S.A. Advances Oncology Pipeline
6-K: Report of foreign private issuer (related to financial reporting)
Innate Pharma Reported Q1 Revenue Of €6.6M Down From €26M YoY; Cash Position Of €113.9M
First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral presentation at AACR 2024Progression of Sanofi-developed NK Cell Engager SAR443579/IPH6101 t
Press Release: Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
Innate Pharma Reports First Quarter 2024 Business Update and Financial Results -- First preclinical data set for IPH45, a pre-IND anti-Nectin-4 Antibody Drug Conjugate, presented as an oral
Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Tuesday, May 14, 2024, at 2 p.m. CEST / 8 a.m. EDT, to give an
No Data